A surprising result of clinical trials of T-DXd in breast and lung cancers has been the degree of clinical benefit observed in patients with low or undetectable HER2 expression as defined by immunohistochemistry (IHC)18,50. This evidence concerns the gene ERBB2 and lung carcinoma.